FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs
The Federal Trade Commission has given final approval to an order against telemedicine company NextMed and its principals, requiring them to stop deceptively advertising weight-loss programs and to stop using deceptive and unfair billing and cancellation practices. View Press Release
Doping at your doorstep: The next Olympic drug crisis could be coming through the mail
By EDDIE PELLS COLORADO SPRINGS, Colo. (AP) — The next Olympic doping scandal could be delivered right to your doorstep. Related Articles Russian skiers and snowboarders allowed by CAS to try to qualify for Winter Olympics USA Gymnastics and Olympic sports watchdog failed to stop coach’s sexual abuse, lawsuits allege Under a cloud, the Olympic […]
Another GLP-1 Alzheimer’s Trial
Well, here’s another report of a GLP-1 agent being tried in Alzheimer’s patients (after this recent post was written). The last one didn’t show much, so let’s have a look. In this trial, 204 patients with mild-to-moderate Alzheimer’s were treated with liraglutide (daily injection) versus placebo for one year. The doses started at 0.6mg and […]
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year
Key Points Eli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio. Lilly and Novo Nordisk dominate this market, which has seen high demand. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) stock recently reached a big milestone, surpassing the level of $1,000. This wasn’t too […]
Trump LIVE: Donald Trump Makes Shocking Admission On US Healthcare System, Slams Obamacare | US News
President Trump held his 9th cabinet meeting on Tuesday, highlighting how his administration’s work in negotiating healthcare with Democrats, calling Obamacare “horrible healthcare.” CMS Administrator Mehmet Oz joins ‘The Sunday Briefing’ to weigh in on Trump’s plan to overhaul U.S. healthcare, new data linking GLP-1 drugs to lower colon cancer deaths and the growing cases […]
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations directly to prescription access and home delivery. Customers meet with independent licensed providers through affiliated medical groups, and when medication is deemed appropriate, prescriptions are routed into a fulfillment network that includes in-house pharmacies, a 503B outsourcing facility […]
Oral GLP-1 Receptor Agonist Orforglipron Beneficial for Adults With Obesity, T2DM
WEDNESDAY, Dec. 3, 2025 — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification versus placebo for adults with obesity or overweight and type…
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and expand their market positions amid soaring demand. Lilly announced meaningful price cuts to its tirzepatide-based obesity drug Zepbound, reducing out-of-pocket costs on […]
Computational Bioengineer Gene Therapy Vector Design
About Us GeneEase discovers novel gene therapies for subclinical conditions overlooked by traditional medicine – genetic disorders affecting millions (alcohol intolerance, lactose intolerance, mild autoimmunity) where existing treatments are inadequate or nonexistent. We use computational biology to identify promising therapeutic targets, design gene therapy approaches (AAV, base editing, other modalities), validate mechanisms in silico, and […]
States retreat from covering drugs for weight loss
Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for the cuts included in President Donald Trump’s broad tax and spending law.